Phase 3 Readout

IKT: Phase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and

Name: Phase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and
Start: 2029-12-01
End: 2029-12-01

December 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2029
Company: Inhibikase Therapeutics, Inc. (IKT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and

December 1, 2029

IKT overview →

Company: Inhibikase Therapeutics, Inc. (IKT)
Indication: Pulmonary Arterial Hypertension